Resultado de búsqueda
Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment.
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy.
11 de mar. de 2019 · The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy.
1 de mar. de 2020 · The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy.
Understanding Immunotherapy Side Effects. Immune checkpoint inhibitors (a type of immunotherapy) offer a promising new way to treat cancer for some patients. But these medicines can cause your immune system to attack normal organs and tissues in your body, affecting the way they work.
6 de mar. de 2017 · We performed network meta‐analysis on hematological (anemia, leukopenia, neutropenia, and thrombocytopenia) and non‐hematological toxicities (diarrhea, infection, and nausea and vomiting). Results. Nine studies with 2317 patients were included.
The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy.
